| Description |
BMS-986242 is an orally active, potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor. BMS-986242 can be used for the research of cancer[1].
|
| Related Catalog |
|
| Target |
IDO1
|
| In Vitro |
BMS-986242 is more prone to oxidative metabolism and less susceptible to glucuronidation. BMS-986242 shows IC50>25 μM for all targets except nAChR a1 (IC50=12.3 μM) and nAChR a7 (IC50>6 μM with ∼20 % max inhibition)[1].
|
| In Vivo |
BMS-986242 (3~30 mg/kg; p.o.; 0~24 hours) exhibits dose-proportional exposure and a statistically significant reduction in kynurenine concentration in the tumor at all three doses[1]. Animal Model: nu/nu Mouse[1] Dosage: 3~30 mg/kg Administration: P.o. Result: Exhibited dose-proportional exposure and a statistically significant reduction in kynurenine concentration in the tumor at all three doses.
|
| References |
[1]. Cherney EC, et al. Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1. ACS Med Chem Lett. 2021;12(2):288-294. Published 2021 Jan 28.
|
